Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124851 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01124851 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 36 participants.
The verdict
NCT01124851, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.
Interventions
- DRUG Placebo
- DRUG ABT-652
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124851
The ClinicalTrials.gov registry entry for NCT01124851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01124851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124851 about?
NCT01124851 is a clinical study titled "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness". The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.
What is the current status of trial NCT01124851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01124851?
The interventions under investigation include: Placebo (DRUG), ABT-652 (DRUG).
Who is sponsoring clinical trial NCT01124851?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.